

Elevate Provider Network Weekly Update

Promoting the value of independent pharmacy patient care

Advocacy

PCMA nearly doubled lobbying expenditures in 2023 over 2022

NCPA, January 29, 2024

PCMA reported spending about \$15.44 million in 2023 on their lobbying efforts. That's a whopping 78 percent more than they spent in 2022. Nearly a third of that was spent in the last quarter of 2023. As Washington gets closer and closer to meaningful reimbursement reform, PCMA is increasing their lobbying. NCPA's Legislative/Legal Defense Fund is doing its best to fight back, however our resources are much more limited than PCMA's.

[Read more](#)

Where are the nation's primary care providers?

Rae Ellen Bichell, KFF Health News, January 30, 2024

"The Association of American Medical Colleges (AAMC) projects a physician shortage of between 17,800 and 48,000 [primary care physicians](#), leading to access issues, especially in rural areas. To bridge this gap, countries like Canada have leveraged pharmacists to provide essential care within their communities. Now, there's an opportunity for pharmacists in the US to step into similar roles as more states continue to grant pharmacists Provider Status. These pharmacists are offering vital patient care services and support where it is needed most. With our expertise and accessibility, pharmacists can play a critical part in expanding healthcare access and improving patient outcomes for underserved populations." Gold Eneyo, Director - Clinical Pharmacy Services, AmerisourceBergen

Politicians keep talking about fixing primary care shortages. A KFF Health News analysis

of federal data has identified more than 180 places in the United States that have been listed as not having enough primary care providers since before 1984.

[Read more](#)

EUA-label Paxlovid extended authorization date

On January 29, the Food and Drug Administration (FDA) [announced](#) an important revision to the Paxlovid Emergency Use Authorization (EUA) Letter of Authorization stating that **EUA-labeled Paxlovid distributed by the U.S. government will remain authorized for use only through March 8, 2024**. Additional information is available in FDA's Paxlovid [letter of authorization](#) dated January 29, 2024. ASPR has worked with Pfizer, the manufacturer of Paxlovid, to ensure that the federal inventory of Paxlovid is the NDA-labeled product.

Please note the return date for EUA-labeled Paxlovid with an expiry of December 2023 or later is **now extended to February 29, 2024**, to ensure a credit to the USG inventory as NDA-labeled supply.

Pharmacies participating in the Federal Retail Pharmacy Therapeutics Program should dispose of any expired product through the manufacturer's return process or on-site following all federal, state, and local regulations. All returns and expired products must be reported on ABC Order.

For specific information on Paxlovid returns, including to request pre-paid shipping visit Inmar PaxlovidEUAreturns.com, email PaxlovidEUAreturns@inmar.com, or call 877-740-6148.

For more information on programs to ensure continued access to COVID-19 therapeutics, please visit the [ASPR Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program](#).

Elevate Provider Network members can receive continued access to COVID therapeutics

Independent pharmacies have played a vital role in facilitating access to Paxlovid treatment within the community. Elevate Provider Network has recently entered into a contract to ensure our network pharmacies can continue to provide access to Paxlovid to their communities. As of December 1, 2023, individuals without commercial insurance may have the option to receive assistance through The USG Patient Assistance Program (USG PAP) operated by Pfizer PAXCESS. This Patient Assistance Program is administered by AssistRx for patients who are uninsured, underinsured, or have government insurance (Medicare/Medicaid/Tricare etc.). The PAXCESS Patient Support Program offers insurance coverage information and provides financial assistance resources to eligible patients who have been prescribed PAXLOVID. Patients can enroll

in the program directly or can be enrolled by their healthcare providers, including pharmacists.

[Healthcare provider site](#)

Looking for COVID-19 vaccines? We've got you covered

Protect your patients today by ordering the vaccine that best fits their needs. Head to ABC Order to purchase a supply of COVID-19 vaccines.

[Order now](#)

4 Ls to increase immunization uptake: A strategic blueprint for pharmacies

Gold Eneyo, Director - Clinical Pharmacy Services, AmerisourceBergen

In the dynamic landscape of healthcare, pharmacies stand at the forefront of immunization services. To maximize your pharmacy's impact and boost vaccine uptake, pharmacies can employ these strategic approaches that emphasize accessibility, education, and community engagement:

- **Leverage:** utilize digital platforms to streamline appointment scheduling, provide vaccine information, and send reminders. A user-friendly online presence enhances convenience and encourages tech-savvy customers to engage with vaccine services. But also encourage spontaneous participation to increase vaccine uptake.
- **Launch:** Initiate an educational campaign within the community to dispel myths and misconceptions about vaccines. Host informational sessions, distribute pamphlets, and leverage social media to provide accurate information and address concerns.
- **Lead:** Train pharmacy staff to be advocates for vaccinations, when customers interact with knowledgeable and approachable staff, they are more likely to feel informed leading to increased vaccine acceptance.
- **Lists:** Utilize your pharmacy and state immunization data analytics lists to identify patients and populations in need of vaccine coverage, allowing pharmacies to tailor their outreach efforts to focus on specific patients and vaccines.

By weaving these strategies into your operations, pharmacies can elevate their role in increasing vaccine uptake and adoption; not only benefiting individual patient health but also contributing to the collective immunity of the community. This reinforces the pharmacy's position as a trusted healthcare ally.

Learn more about starting and expanding immunizations in your pharmacies today! Reach out to your business coach or clinicalolutions@AmerisourceBergen.com.

Help your diabetes patients by dispensing needles and syringes

Effective January 1, 2024, BD pen needles and insulin syringes by embecta have preferred coverage by three of the largest Medicare Part D plans. embecta has the most widespread formulary access in the pen needle and insulin syringe category [source](#), with the aim of reducing patient barriers and potential customer challenges. BD pen needles and insulin syringes are covered by [most health plans](#) across Commercial, Medicaid, and Medicare Part D. Consider dispensing BD pen needles and insulin syringes for your patients with diabetes. You can learn more by visiting *Good Neighbor Pharmacy University*, navigating to the BD/embecta Education tab, and selecting “Did You Know?” from the dropdown menu.

[Visit Good Neighbor Pharmacy University](#)

[Order now](#)

Drive patient adherence with the PrescribeWellness Patient Engagement Center (PEC)

Consistent analysis of your patient’s adherence is vital to your store’s adherence program and to the lives of your patients. The Patient Engagement Center in PrescribeWellness provides interactive

segmented adherence rings showing the number of patients in a current adherence range. Using the ring category pharmacists can place higher priority on patients who are below 80% adherence (dark blue, shown below), allowing your pharmacy efforts to make the most impact. Each segment of the ring is interactive and is reflected in your patient list. The filter button can be used to filter patient lists by demographics, medications, plans and other information to further drill down to targeted patient interventions.



Good Neighbor Pharmacy members can learn more about how the Patient Engagement Center can support high adherence performance by contacting their Business Coach. If additional assistance or training is needed, please

contact support@prescribewellness.com or pharmacyperformance@amerisourcebergen.com.

Generics rebate deadline is March 31

[ThoughtSpot 2024](#) takes place at the Marriott World Center in Orlando, Florida, July 24-27, 2024. Check out the schedule and register today.

Get up to a 4% rebate

Once again, we will be offering the generics rebate. Register before March 31, 2024, and you may be eligible to receive up to 4% off of rebatable generics purchases made between April 1, 2024, and June 30, 2024.*

[Register today and save!](#)

** Subject to meeting the applicable requirements in the ThoughtSpot 2024 Generics Rebate Terms and Conditions. To be eligible and maximize your generic rebate, when utilizing multiple locations/stores, each person must be associated to a unique account number.*



Elevate Provider Network Outcomes opportunities

Outcomes opportunities:

Below are current MTM revenue opportunities available to Elevate Provider Network pharmacies through the Outcomes platform as of January 31, 2024:

Total Outcomes CMR opportunities as of 01/31/24: **36,090**

Potential revenue for the following CMRs: **\$2,117,700**

Additional information regarding Outcomes opportunities can be found on the [Outcomes](#) website.

Contracts

Contracts Signed

- Rightway Healthcare - Pharmacy Network Agreement - BIN 610862 - Effective 2/1/24 - Affects pharmacies Commercial business nationwide.

Contracts Received

- Navitus - NaviCare Addendum - Commercial Broad, NaviCare Narrow Amendment - Medicare Part D Retail Amendment No. 10 (Re-contracts) - Received 1/25/24
- Prime Therapeutics - Rhode Island Consulting Fee Network - Received 1/30/24

Top MAC cases

Each week the Elevate MAC Team analyzes millions of InSite claims, identifying which ones will represent the highest potential financial impact to our members. Although a representative claim might be submitted on behalf of a single Elevate Provider Network pharmacy, the impact may be seen by all our members.

Product Name	NDC	Effective Date	Group	Payer
AMLODIPINE BESYLATE 2.5 MG TAB	68180071909	01/24/2024	1961675	
CLOZAPINE ODT 200 MG TABLET	93537701	01/25/2024	PDPIND	
ESTARYLLA 0.25-0.035 MG TABLET	70700011985	01/22/2024	RXBENHOSP	
FLUOROURACIL 5% CREAM	51672411806	01/25/2024	SWPMED	
METOPROLOL TARTRATE 25 MG TAB	62332011291	01/24/2024	BXMN	
OLMESARTAN MEDOXOMIL 40 MG TAB	68462043890	01/27/2024	EGWPS037	
OSELTAMIVIR 6 MG/ML SUSPENSION	27241013909	01/24/2024	AMCAN	
SERTRALINE HCL 50 MG TABLET	68180035202	01/24/2024	BXMN	
TELMISARTAN 20 MG TABLET	68462019913	01/22/2024	CLOROX	
VARENICLINE STARTING MONTH BOX	49884094499	01/24/2024	LOVESRX	

Have trouble viewing this table? [View in your browser.](#)

Visit the MAC Action Center in the Solutions Portal for a complete list of all MAC Cases with favorable outcomes.

Elevate Provider Network

500 North State College Blvd., Suite 900, Orange, CA 92868

Elevate Help Desk:

Hours: Monday through Friday, 6:00 am PST - 5:00 pm PST
Phone: (888) 880-1388
General Fax: (833) 765-4454
Email: elevate@amerisourcebergen.com

Advocacy: <https://www.wearegnp.com/advocacy>

Outcomes: (515) 237-0001 or www.outcomes.com

Expo Rx Prescription Savings Card: www.wearegnp.com/expo-rx-prescription-savings-card

AmerisourceBergen

